
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
Slides from the FDA GDUFA presentation before the Senate Health, Education, Labor and Pensions Committee in January 2016.
Slides from the FDA GDUFA presentation before the Senate Health, Education, Labor and Pensions Committee in January 2016.
over 10 years ago
Gaining Insight from Process Control Dataover 10 years ago
Phase-Appropriate GMPover 10 years ago
How Important is Data Integrity to Regulatory Bodies?over 10 years ago
Keynote Series Addresses Crucial Industry Issuesover 10 years ago
Polymorph Screening for Identification of Relevant Crystalline Formsover 10 years ago
Building Consensus for E&L Testing Standardsover 10 years ago
Multimode Microplate Reader Improves Sensitivityover 10 years ago
High-Pressure Ion Chromatography System




